{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'clearance < 60 mL/min), gastrointestinal, hepatic, cardiovascular, hematological, or any', 'other system abnormalities that are uncontrolled with standard treatment.', '4. Malignancy: A current malignancy or previous history of cancer in remission for less', 'than 5 years prior to screening (subjects will not be excluded if they had localized', 'carcinoma of the skin that was resected for cure).', '5.', 'Liver Disease: Known pre-existing liver disorders (ie, non-alcoholic fatty liver disease', \"(NALFD) or Gilbert's syndrome), or unstable liver disease (as defined by the presence of\", 'ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices', 'or persistent jaundice), cirrhosis, or known biliary abnormalities.', '6. Prior anti-inflammatory treatment: Subjects who have required a burst of systemic', 'corticosteroids (eg, oral, intravenous, intramuscular corticosteroids) within the 1 month', 'before screening or are scheduled to receive systemic corticosteroids during the study', 'period for another condition, or who have required intranasal corticosteroid drops within', '1 month prior to screening.', '7. Intolerant to mometasone furoate nasal spray.', '8. Specific conditions/concomitant diseases: Subjects with conditions such as:', 'antrochoanal polyps, nasal septal deviation that would occlude at least one nostril; acute', 'sinusitis, invasive fungal rhinosinusitis, neutrophilic polyposis, nasal infection or upper', 'respiratory infection at screening or in the 2 weeks before screening. Subjects requiring', 'chronic systemic antibiotic treatment for rhinosinusitis.', '9. Ongoing rhinitis medicamentosa.', '10. ECG Assessment: Subjects with QTcF > 450 msec for males or QTcF > 470 msec for', 'females on the Screening visit ECG. However, if QTcF is above this prespecified limit', 'and there are no other clinically significant ECG abnormalities in the opinion of the', 'Investigator, the assessment can be repeated in triplicate. The triplicate QTcF values', 'should be averaged by the Investigator to determine eligibility of the subject to enter the', 'Run-in period. However, if any of the triplicate ECGs show a clinically significant', 'abnormality in the opinion of the Investigator, the subject should be excluded, regardless', 'of the average QTcF of the triplicates.', '11. Alcohol/Marijuana/Illicit Drugs/Substance Abuse: A known or suspected history of', 'alcohol misuse, marijuana, illicit drugs, or substance abuse within 12 months prior to', 'Screening visit.', '12. Smoking history: Asthma or COPD patients that are current smokers (any substance),', 'or', 'former smokers with a smoking history of > 10 pack-years [(number of cigarettes per', 'day/20) X number of years smoked]. A former smoker is defined as a subject who quit', 'smoking at least 6 months prior to Screening visit. This includes electronic cigarettes and', 'vaping.', '13. Immunodeficiency: A known immunodeficiency, including that due to human', 'immunodeficiency virus (HIV), other than that explained by systemic corticosteroid use.', '14. Investigational medications: Subjects who have received treatment with an', 'investigational medication within the past 30 days or within 5 half-lives of the', '27', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'medication, whichever is longer, prior to Screening visit (this also includes', 'investigational formulations of marketed products).', '15. Receiving prohibited medications: Refer to Appendix 10 (Section 10.10) for more', 'details.', 'a. Regular use of systemic corticosteroids or immunosuppressive therapies including', 'methotrexate or azathioprine', 'b. Monoclonal antibodies used in the treatment of asthma', 'c. Medications, food or drink that are moderate or strong CYP3A4 inhibitors or inducers', 'd.', 'Other medications that have the potential for interaction with GB001', 'e. Medications that have a black-box warning for hepatic toxicity.', '16. Prior participation in a study with GB001: Subjects who previously participated in', 'a study with GB001 (also named PTR-36 or ADC3680).', '17. Hypersensitivity: A known sensitivity to GB001 or any of its excipients. Subjects with', 'rare hereditary problems of galactose intolerance, the Lapp lactase deficiency,', 'or glucose-galactose malabsorption. Subjects with mild-moderate lactose intolerance', 'are not excluded. Subjects with sensitivity or intolerance to aspirin (ie, subjects with', 'aspirin-exacerbated respiratory disease [AERD] with or without desensitization).', '18. Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled', 'if they are planning to become pregnant during the time of study participation. A serum', 'pregnancy test is required of all females of child-bearing potential at Screening.', '19. Adherence: Subjects who have a known lack of adherence to medications such as INCS.', '20. Body Mass Index (BMI): BMI is > 40 kg/m\u00b2.', '21. Participation: Subject has any other condition or reason that, in the opinion of the', 'Investigator, would prohibit the subject from participating in the study.', '22. Participation in another clinical study: Subjects currently participating in an', 'interventional clinical study with a biologic agent or who have received study drug in', 'another clinical study are not to be considered for participation until the completion of the', 'safety follow-up visit or following a non-investigational drug period of no less than five', 'half-lives. Subjects may not participate in another interventional clinical trial while', 'enrolled in this study.', '28', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}